Recent literature data and a growing body of evidence demonstrated that PSMA-targeted PET ameliorates staging and restaging of prostate cancer patients, changing the management in a significant percentage of cases [11,12]. This evidence concerns the gene FOLH1 and Familial prostate cancer.